BioAge Labs, Inc. (NASDAQ:BIOA) Given Average Rating of “Moderate Buy” by Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $43.50.

A number of research firms have recently issued reports on BIOA. Morgan Stanley set a $23.00 price target on BioAge Labs in a research report on Wednesday, February 4th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Oppenheimer began coverage on shares of BioAge Labs in a research note on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price objective on the stock. BTIG Research began coverage on shares of BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Roth Mkm began coverage on BioAge Labs in a research report on Wednesday. They set a “buy” rating and a $36.00 target price on the stock.

BioAge Labs Stock Performance

BioAge Labs stock opened at $17.05 on Friday. The company has a market capitalization of $757.87 million, a PE ratio of -7.10 and a beta of 0.99. The company has a 50 day moving average price of $17.45 and a 200-day moving average price of $16.44. BioAge Labs has a fifty-two week low of $3.88 and a fifty-two week high of $24.00.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, analysts forecast that BioAge Labs will post -2.59 earnings per share for the current year.

Hedge Funds Weigh In On BioAge Labs

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after buying an additional 171,426 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of BioAge Labs in the 2nd quarter valued at about $64,000. Marshall Wace LLP grew its position in shares of BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after buying an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of BioAge Labs during the 2nd quarter worth approximately $182,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.